Amneal’s Rytary Follow-On Crexont Could Hit $500m In Sales
Forecasting 3%+ Market Share By Year End; ‘Positioned For Leading Branded Parkinson’s Drug’
Amneal has spoken excitedly about its Crexont (carbidopa/levodopa) extended-release capsules as the Parkinson’s disease drug passes six months on the market.
